새로운 알츠하이머 치료제의 안전성 유효성에 관한 체계적 문헌고찰
Systemic Literature Review Study on the Efficacy and Safety of Novel Alzheimer’s Disease Treatments
4
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Innovative Alzheimer’s disease drugs received approval in the United States in 2021 and 2023. This study aims to assess the safety and efficacy of these novel treatments, elucidate their mechanisms of action, and compare their impact on cognitive function improvement with approved drugs. Methods: We conducted a comprehensive search of pivotal clinical studies related to Alzheimer’s disease treatments in PubMed/Medline, Embase, and the Cochrane Library databases from January 1st, 2020 to December 31st, 2022. Meta-analysis was performed using RevMan 5.4 software. Results: A total of 14 studies were included in this systematic review. When compared to the placebo, the new drugs did not exhibit a statistically significant effect on MMSE (Mini- Mental State Examination) (mean difference= −0.04, 95% confidence intervals [CIs]: −0.31, 0.23, N=3662, I2=0%). However, they demonstrated a significant impact on ADAS-cog (Alzheimer’s Disease Assessment Scale-Cognitive Subscale) (standardized mean difference= −0.15, 95% CIs: −0.2, −0.1, N=6710, I2=17%). When compared to the approved drugs, the new drugs showed a statistically significantly lower effect on MMSE (test for subgroup difference Chi2=23.13, N = 5870, p<0.00001) but showed only a trend of decreased efficacy on ADAS-cog (Chi2=1.16, N = 8670, p=0.28). Conclusion: New drugs yielded diverse clinical endpoint results compared to the placebo, and in comparison to existing approved drugs, they exhibited lower efficacy in improving cognitive function. The safety profile of these new drugs, as reported in clinical trials, was generally well-tolerated.
Abstract
Background: Innovative Alzheimer’s disease drugs received approval in the United States in 2021 and 2023. This study aims to assess the safety and efficacy of these novel treatments, elucidate their mechanisms of action, and compare their impact on cognitive function improvement with approved drugs. Methods: We conducted a comprehensive search of pivotal clinical studies related to Alzheimer’s disease treatments in PubMed/Medline, Embase, and the Cochrane Library databases from January 1st, 2020 to December 31st, 2022. Meta-analysis was performed using RevMan 5.4 software. Results: A total of 14 studies were included in this systematic review. When compared to the placebo, the new drugs did not exhibit a statistically significant effect on MMSE (Mini- Mental State Examination) (mean difference= −0.04, 95% confidence intervals [CIs]: −0.31, 0.23, N=3662, I2=0%). However, they demonstrated a significant impact on ADAS-cog (Alzheimer’s Disease Assessment Scale-Cognitive Subscale) (standardized mean difference= −0.15, 95% CIs: −0.2, −0.1, N=6710, I2=17%). When compared to the approved drugs, the new drugs showed a statistically significantly lower effect on MMSE (test for subgroup difference Chi2=23.13, N = 5870, p<0.00001) but showed only a trend of decreased efficacy on ADAS-cog (Chi2=1.16, N = 8670, p=0.28). Conclusion: New drugs yielded diverse clinical endpoint results compared to the placebo, and in comparison to existing approved drugs, they exhibited lower efficacy in improving cognitive function. The safety profile of these new drugs, as reported in clinical trials, was generally well-tolerated.
참고문헌 (31)
- Van Duijn C, "Alzheimer’s disease, genetic and environmental factors", Eur Psychiatry, 13, pp.217~218 (1998)
- Service NHI, "National health insurance corporation-alzheimer’s(f00 and g30)treatment statistics for the number of patients and total treatment costs", Public Data Portal, ~ (2022)
- Tariot PN, "A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with alzheimer’s disease in the nursing home setting", J Am Geriatr Soc, 49(12), pp.1590~1599 (2001)
- "Therapeutics: Tacrine" (2023)[URL]
- "Drugs@fda: Fda-approved drugs" (2021)[URL]
- 김정은, "우리나라 건강보험 청구자료를 이용한 알츠하이머성 치매 치료제의 사용현황 분석", 한국임상약학회지, 24(4), pp.255~264 (2014), 한국임상약학회
- Huang L-K, "Clinical trials of new drugs for alzheimer disease", J Biomed Sci, 27(1), pp.1~13 (2020)
- "Kpic drug classification -pharmaceutical information service" (2021)[URL]
- Zhu X-C, "Rate of early onset alzheimer’s disease : A systematic review and meta-analysis", Ann Transl Med, 3(3), pp.38~ (2015)
- Mejías-Trueba M, "Systematic review of the efficacy of statins for the treatment of alzheimer’s disease", Clin Med, 18(1), pp.54~ (2018)
- Yu J-T, "Evidence-based prevention of alzheimer’s disease : Systematic review and meta-analysis of 243observational prospective studies and 153 randomised controlled trials", J Neurol Neurosurg Psychiatry, 91(11), pp.1201~1209 (2020)
- 박혜원, "코로나바이러스감염증-19로 입원한 환자들에 대한 아연의 임상적 효과: 체계적 문헌고찰 및 메타분석", 한국임상약학회지, 31(2), pp.136~144 (2021), 한국임상약학회[DOI]
- "Chapter 8: Assessing risk of bias in a randomized trial" (2022)[URL]
- 조재훈, "메타분석의 이론과 실제", Journal of Rhinology, 27(2), pp.83~89 (2020), 대한비과학회[DOI]
- Sperling R, "Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical alzheimer disease : A truncated randomized phase 2b", 3 clinical trial, 2021, pp.78(3), 293~301
- Cohen S, "Item-level analysis of clinical measures in patients with early symptomatic alzheimer’s disease following treatment with high-dose aducanumab in the phase 3study emerge", Alzheimers Dement, 17(S9), pp.e057619~ (2021)
- Budd Haeberlein S, "Two randomized phase 3 studies of aducanumab in early alzheimer’s disease", J Prev Alzheimers Dis, 9(2), pp.197~210 (2022)
- Mintun MA, "Donanemab in early alzheimer’s disease", N Engl J Med, 384(18), pp.1691~1704 (2021)
- Ostrowitzki S, "Evaluating the safety and efficacy of crenezumab vs placebo in adults with early alzheimer disease : Two phase 3 randomized placebo-controlled trials", JAMA Neurol, 79(11), pp.1113~1121 (2022)
- Swanson C, "Lecanemab, an anti-Aβ Protofibril antibody : Updated data from a randomized, doubleblind phase 2b proof of concept clinical trial and open-label extension in early alzheimer’s disease", J Neurol Sci, 429, pp.100~ (2021)
- van Dyck CH, "Lecanemab in early alzheimer’s disease", N Engl J Med, 388(1), pp.9~21 (2023)
- Teng E, "Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease : A randomized clinical trial", JAMA Neurol, 79(8), pp.758~767 (2022)
- Xiao S, "A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate alzheimer's dementia", Alzheimers Res Ther, 13(1), pp.62~ (2021)
- Prins ND, "A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild alzheimer’s disease", Alzheimers Res Ther, 13(1), pp.106~ (2021)
- Hirst WD, "Sb-399885 is a potent, selective 5-ht6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models", Eur J Pharmacol, 553(1-3), pp.109~119 (2006)
- Nirogi R, "Effects of masupirdine(suvn-502)on agitation", aggression and psychosis in patients with probable alzheimer’s disease : A post hoc analysis, 2022, pp.18, e062695~
- Haddad HW, "Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of alzheimer’s disease : A comprehensive review", Health Psychol Res, 10(1), pp.31925~ (2022)
- Breijyeh Z, "Comprehensive review on alzheimer’s disease : Causes and treatment", Molecules, 25(24), pp.5789~ (2020)
- Hannestad J, "Safety and tolerability of grf6019 infusions in severe alzheimer’s disease : A phase ii doubleblind placebo-controlled trial", J Alzheimers Dis, 81(4), pp.1649~1662 (2021)
- Koh SH, "Efficacy and safety of gv1001 in patients with moderate-to-severe alzheimer’s disease already receiving donepezil : A phase 2 randomized, double-blind, placebocontrolled, multicenter clinical trial", Alzheimers Res Ther, 13(1), pp.66~ (2021)
- Wang T, "A phase ii randomized trial of sodium oligomannate in alzheimer’s dementia", Alzheimers Res Ther, 12(1), pp.110~ (2020)